HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aidan Fry

With over 20 years of experience of reporting on the global pharmaceutical industry, Aidan focuses in his role as editor of Generics bulletin particularly on commercial, regulatory and legal issues affecting the generic, biosimilar, value-added and OTC medicines industries. This includes in-depth analyses of corporate strategy, legislative changes, legal precedents and product perspectives. He regularly interviews leading industry executives and moderates prestigious events. Aidan also oversees the Global Generics & Biosimilars Awards. Aidan speaks fluent German and has a particular affection for maps.
Set Alert for Articles By Aidan Fry

Latest From Aidan Fry

Amneal Starts Seeking International Partners

In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.

Business Strategies China

Teva Beats Janssen On Canadian Bortezomib Compensation

Teva is eligible for compensation due to having been kept off the Canadian bortezomib market by Janssen suing for infringement of two patents that were subsequently found to be obvious.

Intellectual Property Canada

Accord Strikes Thiotepa Deal With Adienne

Accord Healthcare has secured commercial rights to Adienne’s novel lyophilized formulation of thiotepa in Europe, extending its portfolio of cancer treatments.

Value-Added Medicines Cancer

Dutch Decision Invalidates Truvada SPC

Gilead’s Truvada is not entitled to an SPC in the Netherlands because the patent on which the SPC application referred mentions only one of the two active ingredients in the combination antiretroviral.

Intellectual Property Netherlands

Teva To Return With Vincristine In US

Amid market shortages of the pediatric cancer treatment as Pfizer struggles to meet demand, Teva has decided to resume producing vincristine in the US and plans to start shipments next year.

Cancer United States

Apotex Is Blocked On Canadian Abiraterone

Apotex has failed to convince a Canadian federal court that a patent protecting Janssen’s Zytiga abiraterone brand until August 2027 is invalid and not infringed by its proposed generic version of the prostate-cancer treatment.

Intellectual Property Canada
See All
UsernamePublicRestriction

Register